Anti-SARS-CoV-1, Spike (Clone COV1-80)-Purified No Carrier Protein, Clone: [COV1-80], Monoclonal
Biozol Catalog Number:
ABI-12-8259-250
Supplier Catalog Number:
12-8259-250
Alternative Catalog Number:
ABI-12-8259-250-250UG
Manufacturer:
Abeomics
Category:
Antikörper
Specificity: COV1-80 targets the prefusion spike protein of SARS-CoV-1 and SARS-CoV-2. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-80 monoclonal antibody is cross-reactive, targeting the spike protein of both SARS-CoV-1 and SARS-CoV-2. While it does not block the ACE2 receptor, COV1-80 still functions as a neutralizing antibody, meaning it can inhibit the viruss capacity to infect host cells. The exact epitope that COV1-80 binds to remains unidentified, highlighting the need for further research to understand its mechanism of action fully. Nonetheless, the demonstrated neutralizing activity of COV1-80 makes it a promising candidate for therapeutic strategies, particularly in combination therapies that target multiple viral epitopes for enhanced effectiveness.
Clonality:
Monoclonal
Clone Designation:
[COV1-80]
Purity:
Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Target:
SARS-CoV-1
Application Dilute:
N
* VAT and and shipping costs not included. Errors and price changes excepted
